Investing16d
FDA expands approval for cystic fibrosis drug Trikafta
TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR) ...
Investing16d
FDA expands approval for cystic fibrosis drug Trikafta
TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR) ...
Nasdaq16d
Vertex announces FDA exands approval for Trikafta
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...
Investing16d
FDA expands approval for cystic fibrosis drug Trikafta
TRIKAFTA, a combination of elexacaftor, tezacaftor, and ivacaftor, is designed to enhance the function of the defective protein caused by cystic fibrosis transmembrane conductance regulator (CFTR ...
Business Wire16d
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
Reuters17d
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The approval also helps shield from erosion of sales when Trikafta loses its patent, said William Blair analyst Myles Minter ahead of the decision. Cystic fibrosis is an inherited disease in which ...
MedPage Today17d
Next-in-Class Once-Daily Pill Approved for Cystic Fibrosis
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved a once-daily oral combination of ...
The Huntsville Item17d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
The Phase 3 studies in people with CF ages 12 years and older met their primary endpoint (non-inferiority on absolute change from baseline in ppFEV 1 compared to TRIKAFTA) and all key secondary ...
Tom's Guide17d
The best Google Photos alternatives in 2025
Google Photos has long been a favorite for storing and sharing memories, but recent changes have left many seeking alternatives. A good photo storage platform should offer more than just space.
The New York Times19d
The Photos that Defined 2024
Doug’s heart pounded when he realized what was happening. Then instinct took over. Doug kept taking pictures, at a shutter speed of one eight-thousandth of a second, capturing an image that ...
W magazine19d
The Must-See Art Shows and Exhibitions of 2025
George Condo’s new exhibit, titled Pastels, will be split across two galleries: Hauser & Wirth’s SoHo location and Sprüth Magers on the Upper East Side. This two-part show centered around the ...